276 related articles for article (PubMed ID: 11054678)
1. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
Middleton MR; Lee SM; Arance A; Wood M; Thatcher N; Margison GP
Int J Cancer; 2000 Nov; 88(3):469-73. PubMed ID: 11054678
[TBL] [Abstract][Full Text] [Related]
2. Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea.
Philip PA; Souliotis VL; Harris AL; Salisbury A; Tates AD; Mitchell K; van Delft JH; Ganesan TS; Kyrtopoulos SA
Clin Cancer Res; 1996 Feb; 2(2):303-10. PubMed ID: 9816173
[TBL] [Abstract][Full Text] [Related]
3. O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
Middleton MR; Lunn JM; Morris C; Rustin G; Wedge SR; Brampton MH; Lind MJ; Lee SM; Newell DR; Bleehen NM; Newlands ES; Calvert AH; Margison GP; Thatcher N
Br J Cancer; 1998 Nov; 78(9):1199-202. PubMed ID: 9820180
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Plummer ER; Middleton MR; Jones C; Olsen A; Hickson I; McHugh P; Margison GP; McGown G; Thorncroft M; Watson AJ; Boddy AV; Calvert AH; Harris AL; Newell DR; Curtin NJ
Clin Cancer Res; 2005 May; 11(9):3402-9. PubMed ID: 15867241
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
Spiro TP; Liu L; Majka S; Haaga J; Willson JK; Gerson SL
Clin Cancer Res; 2001 Aug; 7(8):2309-17. PubMed ID: 11489806
[TBL] [Abstract][Full Text] [Related]
6. O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
Bobola MS; Silber JR; Ellenbogen RG; Geyer JR; Blank A; Goff RD
Clin Cancer Res; 2005 Apr; 11(7):2747-55. PubMed ID: 15814657
[TBL] [Abstract][Full Text] [Related]
7. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
[TBL] [Abstract][Full Text] [Related]
8. O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.
Watson AJ; Middleton MR; McGown G; Thorncroft M; Ranson M; Hersey P; McArthur G; Davis ID; Thomson D; Beith J; Haydon A; Kefford R; Lorigan P; Mortimer P; Sabharwal A; Hayward O; Margison GP
Br J Cancer; 2009 Apr; 100(8):1250-6. PubMed ID: 19367283
[TBL] [Abstract][Full Text] [Related]
9. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Aghi M; Rabkin S; Martuza RL
J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
Zheng M; Bocangel D; Ramesh R; Ekmekcioglu S; Poindexter N; Grimm EA; Chada S
Mol Cancer Ther; 2008 Dec; 7(12):3842-51. PubMed ID: 19056673
[TBL] [Abstract][Full Text] [Related]
11. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
Chinot OL; Barrié M; Fuentes S; Eudes N; Lancelot S; Metellus P; Muracciole X; Braguer D; Ouafik L; Martin PM; Dufour H; Figarella-Branger D
J Clin Oncol; 2007 Apr; 25(12):1470-5. PubMed ID: 17442989
[TBL] [Abstract][Full Text] [Related]
12. Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells.
Sabharwal A; Waters R; Danson S; Clamp A; Lorigan P; Thatcher N; Margison GP; Middleton MR
Melanoma Res; 2011 Dec; 21(6):502-8. PubMed ID: 19561552
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Hochhauser D; Glynne-Jones R; Potter V; Grávalos C; Doyle TJ; Pathiraja K; Zhang Q; Zhang L; Sausville EA
Mol Cancer Ther; 2013 May; 12(5):809-18. PubMed ID: 23443801
[TBL] [Abstract][Full Text] [Related]
14. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.
Levin N; Lavon I; Zelikovitsh B; Fuchs D; Bokstein F; Fellig Y; Siegal T
Cancer; 2006 Apr; 106(8):1759-65. PubMed ID: 16541434
[TBL] [Abstract][Full Text] [Related]
15. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.
Zauderer MG; Drilon A; Kadota K; Huberman K; Sima CS; Bergagnini I; Sumner DK; Travis WD; Heguy A; Ginsberg MS; Holodny AI; Riely GJ; Kris MG; Krug LM; Pietanza MC
Lung Cancer; 2014 Nov; 86(2):237-40. PubMed ID: 25194640
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.
Boeckmann L; Nickel AC; Kuschal C; Schaefer A; Thoms KM; Schön MP; Thomale J; Emmert S
Melanoma Res; 2011 Jun; 21(3):206-16. PubMed ID: 21460749
[TBL] [Abstract][Full Text] [Related]
17. Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins.
Querfeld C; Rosen ST; Guitart J; Rademaker A; Pezen DS; Dolan ME; Baron J; Yarosh DB; Foss F; Kuzel TM
Clin Cancer Res; 2011 Sep; 17(17):5748-54. PubMed ID: 21747120
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
[TBL] [Abstract][Full Text] [Related]
19. A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo.
Chen TC; Cho HY; Wang W; Nguyen J; Jhaveri N; Rosenstein-Sisson R; Hofman FM; Schönthal AH
Cancer Lett; 2015 Mar; 358(2):144-151. PubMed ID: 25524552
[TBL] [Abstract][Full Text] [Related]
20. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
